The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

• Status: NOT_YET_RECRUITING
• Trial end date: 2026-08-31

Summary

To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer

• Phase: PHASE2

Details

• Lead Sponsor: Fujian Cancer Hospital
• Treatments: anlotinib; Oxaliplatin; Tegafur; tislelizumab